The Role of DNA & RNA in Comprehensive Genomic Profiling

Experts discuss the critical importance of including RNA sequencing in comprehensive biomarker testing for non-small cell lung cancer (NSCLC). They highlight that while DNA-based NGS is foundational, it is insufficient for reliably detecting key gene fusions like RET and ROS1.

The experts strongly advocates for using combined DNA and RNA NGS panels as the new standard of care. They note that DNA-only testing is largely obsolete for tissue biopsies, as it can miss these actionable alterations, potentially denying patients access to highly effective targeted therapy. This approach is deemed especially vital in stage III and metastatic settings where the identification of every actionable driver is paramount. The experts also mention using ctDNA (liquid biopsy) alongside tissue NGS to aid in risk stratification and monitoring.